IBD-PODCAST Spain: A Close Look at Current Daily Clinical Practice in IBD Management.
Crohn’s disease
Inflammatory bowel diseases
STRIDE II recommendations
Treat to target strategy
Ulcerative colitis
Journal
Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782
Informations de publication
Date de publication:
13 Jan 2024
13 Jan 2024
Historique:
received:
28
07
2023
accepted:
10
10
2023
medline:
13
1
2024
pubmed:
13
1
2024
entrez:
13
1
2024
Statut:
aheadofprint
Résumé
Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) that contributes in part to irreversible bowel damage and long-term complications, reduced quality of life, invalidity, and economic burden. Suboptimal control of IBD is associated with higher healthcare resource utilization (HCRU), impaired quality of life (QoL), and reduced work productivity. The IBD-PODCAST study aimed to assess the proportion of IBD patients with suboptimal control and its associated impact. IBD-PODCAST is a cross-sectional, multicenter study that aimed to characterize the CD and UC population with optimal or suboptimal control according to the STRIDE-II criteria and patient- and physician-reported measures. Here we present the results of the Spanish cohort (n = 396). A total of 104/196 (53.1%) CD and 83/200 (41.5%) UC patients were found to have suboptimal disease control. Long-term treatment targets according to STRIDE-II were applied in 172 (87.8%) CD and 181 (90.5%) UC patients. 125 of 172 (72.7%) CD and 74 of 181 (40.9%) UC patients were currently treated with targeted immunomodulators. Patients with CD and UC and suboptimal disease control showed impaired QoL, higher HCRU and direct costs, and also loss of work productivity compared to those with optimal control. Despite a high rate of targeted immunomodulator therapy, a substantial proportion of IBD patients show suboptimal disease control according to the STRIDE II criteria. Those patients with suboptimal disease control exhibit impaired QoL, less work productivity, and higher HCRU, suggesting that there is considerable need for better treatment approaches in IBD.
Sections du résumé
BACKGROUND
BACKGROUND
Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD) that contributes in part to irreversible bowel damage and long-term complications, reduced quality of life, invalidity, and economic burden. Suboptimal control of IBD is associated with higher healthcare resource utilization (HCRU), impaired quality of life (QoL), and reduced work productivity.
AIMS
OBJECTIVE
The IBD-PODCAST study aimed to assess the proportion of IBD patients with suboptimal control and its associated impact.
METHODS
METHODS
IBD-PODCAST is a cross-sectional, multicenter study that aimed to characterize the CD and UC population with optimal or suboptimal control according to the STRIDE-II criteria and patient- and physician-reported measures. Here we present the results of the Spanish cohort (n = 396).
RESULTS
RESULTS
A total of 104/196 (53.1%) CD and 83/200 (41.5%) UC patients were found to have suboptimal disease control. Long-term treatment targets according to STRIDE-II were applied in 172 (87.8%) CD and 181 (90.5%) UC patients. 125 of 172 (72.7%) CD and 74 of 181 (40.9%) UC patients were currently treated with targeted immunomodulators. Patients with CD and UC and suboptimal disease control showed impaired QoL, higher HCRU and direct costs, and also loss of work productivity compared to those with optimal control.
CONCLUSION
CONCLUSIONS
Despite a high rate of targeted immunomodulator therapy, a substantial proportion of IBD patients show suboptimal disease control according to the STRIDE II criteria. Those patients with suboptimal disease control exhibit impaired QoL, less work productivity, and higher HCRU, suggesting that there is considerable need for better treatment approaches in IBD.
Identifiants
pubmed: 38217680
doi: 10.1007/s10620-023-08220-9
pii: 10.1007/s10620-023-08220-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Sairenji T, Collins KL, Evans DV. An Update on Inflammatory Bowel Disease. Prim Care. 2017;44:673–692.
pubmed: 29132528
doi: 10.1016/j.pop.2017.07.010
Torres J, Mehandru S, Colombel JF, Peyrin-Biroulet L. Crohn’s disease. Lancet. 2017;389(10080):1741–1755.
pubmed: 27914655
doi: 10.1016/S0140-6736(16)31711-1
Levine JS, Burakoff R. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2011;7:235–241.
pubmed: 21857821
Harbord M, Annese V, Vavricka SR et al. The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. J Crohns Colitis. 2016;10:239–254.
pubmed: 26614685
doi: 10.1093/ecco-jcc/jjv213
Hedin CRH, Vavricka SR, Stagg AJ et al. The Pathogenesis of Extraintestinal Manifestations: Implications for IBD Research, Diagnosis, and Therapy. J Crohns Colitis. 2019;13:541–554.
pubmed: 30445584
doi: 10.1093/ecco-jcc/jjy191
Vavricka SR, Schoepfer A, Scharl M et al. Extraintestinal Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21:1982–1992.
pubmed: 26154136
doi: 10.1097/MIB.0000000000000392
Collaborators GBDIBD. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:17–30.
Burisch J, Jess T, Martinato M, Lakatos PL, EpiCom E. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7:322–337.
pubmed: 23395397
doi: 10.1016/j.crohns.2013.01.010
Maldonado-Contreras A. Food as Treatment of Inflammatory Bowel Diseases. Infect Immun. 2022;90:e0058321.
pubmed: 35323020
doi: 10.1128/iai.00583-21
Kaplan GG, Windsor JW. The four epidemiological stages in the global evolution of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2021;18:56–66.
pubmed: 33033392
doi: 10.1038/s41575-020-00360-x
Fumery M, Singh S, Dulai PS et al. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. Clin Gastroenterol Hepatol. 2018;16:343–56 e3.
pubmed: 28625817
doi: 10.1016/j.cgh.2017.06.016
Le Berre C, Ananthakrishnan AN, Danese S, Singh S, Peyrin-Biroulet L. Ulcerative Colitis and Crohn’s Disease Have Similar Burden and Goals for Treatment. Clin Gastroenterol Hepatol. 2020;18:14–23.
pubmed: 31301452
doi: 10.1016/j.cgh.2019.07.005
Leone D, Gilardi D, Corro BE et al. Psychological Characteristics of Inflammatory Bowel Disease Patients: A Comparison Between Active and Nonactive Patients. Inflamm Bowel Dis. 2019;25:1399–1407.
pubmed: 30689871
doi: 10.1093/ibd/izy400
van Gennep S, Evers SW, Rietdijk ST et al. High Disease Burden Drives Indirect Costs in Employed Inflammatory Bowel Disease Patients: The WORK-IBD Study. Inflamm Bowel Dis. 2021;27:352–363.
pubmed: 32378704
doi: 10.1093/ibd/izaa082
Singh A, Gupta YK, Dhaliwal AS et al. Inflammatory bowel disease (IBD)-disk accurately predicts the daily life burden and parallels disease activity in patients with IBD. Intest Res. 2022;21:375–384.
pubmed: 36245342
pmcid: 10397543
doi: 10.5217/ir.2022.00037
The Lancet Gastroenterology H. The economic burden of inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2023;8:391.
Burisch J, Zhao M, Odes S et al. The cost of inflammatory bowel disease in high-income settings: a Lancet Gastroenterology & Hepatology Commission. Lancet Gastroenterol Hepatol. 2023;8:458–492.
pubmed: 36871566
doi: 10.1016/S2468-1253(23)00003-1
Bouguen G, Levesque BG, Feagan BG et al. Treat to target: a proposed new paradigm for the management of Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13:1042–50.e2.
pubmed: 24036054
doi: 10.1016/j.cgh.2013.09.006
Colombel JF, D’Haens G, Lee WJ, Petersson J, Panaccione R. Outcomes and Strategies to Support a Treat-to-target Approach in Inflammatory Bowel Disease: A Systematic Review. J Crohns Colitis. 2020;14:254–266.
pubmed: 31403666
doi: 10.1093/ecco-jcc/jjz131
Peyrin-Biroulet L, Sandborn W, Sands BE et al. Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target. Am J Gastroenterol. 2015;110:1324–1338.
pubmed: 26303131
doi: 10.1038/ajg.2015.233
Turner D, Ricciuto A, Lewis A et al. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2021;160:1570–1583.
pubmed: 33359090
doi: 10.1053/j.gastro.2020.12.031
National Guideline Centre (UK). Treat-to-target: Rheumatoid arthritis in adults: diagnosis and management: Evidence review. C. London 2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK577119/ .
Garcia NM, Cohen NA, Rubin DT. Treat-to-target and sequencing therapies in Crohn’s disease. United European Gastroenterol J. 2022;10:1121–1128.
pubmed: 36507876
pmcid: 9752313
doi: 10.1002/ueg2.12336
Ungaro R, Colombel JF, Lissoos T, Peyrin-Biroulet L. A Treat-to-Target Update in Ulcerative Colitis: A Systematic Review. Am J Gastroenterol. 2019;114:874–883.
pubmed: 30908297
pmcid: 6553548
doi: 10.14309/ajg.0000000000000183
Dulai PS, Feagan BG, Sands BE et al. Prognostic Value of Fecal Calprotectin to Inform Treat-to-Target Monitoring in Ulcerative Colitis. Clin Gastroenterol Hepatol. 2023;21:456–66 e7.
pubmed: 35934286
doi: 10.1016/j.cgh.2022.07.027
Ungaro RC, Yzet C, Bossuyt P et al. Deep Remission at 1 Year Prevents Progression of Early Crohn’s Disease. Gastroenterology. 2020;159:139–147.
pubmed: 32224129
doi: 10.1053/j.gastro.2020.03.039
Colombel JF, Panaccione R, Bossuyt P et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017;390(10114):2779–2789.
pubmed: 29096949
doi: 10.1016/S0140-6736(17)32641-7
Danese S, Vermeire S, D’Haens G et al. Treat to target versus standard of care for patients with Crohn’s disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial. Lancet Gastroenterol Hepatol. 2022;7:294–306.
pubmed: 35120656
doi: 10.1016/S2468-1253(21)00474-X
Selinger CP, Parkes GC, Bassi A et al. A multi-centre audit of excess steroid use in 1176 patients with inflammatory bowel disease. Alimentary Pharmacology & Therapeutics. 2017;46:964–973.
doi: 10.1111/apt.14334
Van Assche G, Dignass A, Panes J et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Definitions and diagnosis. J Crohns Colitis. 2010;4:7–27.
pubmed: 21122488
doi: 10.1016/j.crohns.2009.12.003
Irvine EJ, Zhou Q, Thompson AK. The Short Inflammatory Bowel Disease Questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. CCRPT Investigators. Canadian Crohn’s Relapse Prevention Trial. Am J Gastroenterol. 1996;91:1571–1578.
pubmed: 8759664
Smith E, Lai JS, Cella D. Building a measure of fatigue: the functional assessment of Chronic Illness Therapy Fatigue Scale. PM R. 2010;2:359–363.
pubmed: 20656617
doi: 10.1016/j.pmrj.2010.04.017
Khan S, Dasrath F, Farghaly S et al. Unmet Communication and Information Needs for Patients with IBD: Implications for Mobile Health Technology. Br J Med Med Res. 2016;12:1–11.
doi: 10.9734/BJMMR/2016/21884
Knisely MR, Conley YP, Szigethy E. Cytokine Genetic Variants and Health-Related Quality of Life in Crohn’s Disease: An Exploratory Study. Biol Res Nurs. 2019;21:544–551.
pubmed: 31272196
pmcid: 6854428
doi: 10.1177/1099800419860906
Perera LP, Bhandari S, Liu R et al. Advanced Age Does Not Negatively Impact Health-Related Quality of Life in Inflammatory Bowel Disease. Digestive Diseases and Sciences. 2018;63:1787–1793.
pubmed: 29713985
doi: 10.1007/s10620-018-5076-6
Ghosh S, Louis E, Beaugerie L et al. Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2017;23:333–340.
pubmed: 28146002
doi: 10.1097/MIB.0000000000001033
Bennebroek Evertsz F, Nieuwkerk PT, Stokkers PC et al. The patient simple clinical colitis activity index (P-SCCAI) can detect ulcerative colitis (UC) disease activity in remission: a comparison of the P-SCCAI with clinician-based SCCAI and biological markers. J Crohns Colitis. 2013;7:890–900.
pubmed: 23269224
doi: 10.1016/j.crohns.2012.11.007
Williet N, Sarter H, Gower-Rousseau C et al. Patient-reported Outcomes in a French Nationwide Survey of Inflammatory Bowel Disease Patients. J Crohns Colitis. 2017;11:165–174.
pubmed: 27516406
doi: 10.1093/ecco-jcc/jjw145
Barberio B, Zamani M, Black CJ, Savarino EV, Ford AC. Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2021;6:359–370.
pubmed: 33721557
doi: 10.1016/S2468-1253(21)00014-5
Louis EJ, Reinisch W, Schwartz DA et al. Adalimumab Reduces Extraintestinal Manifestations in Patients with Crohn’s Disease: A Pooled Analysis of 11 Clinical Studies. Advances in therapy. 2018;35:563–576.
pubmed: 29516410
pmcid: 5910478
doi: 10.1007/s12325-018-0678-0
Parian AM, Obi M, Fleshner P, Schwartz DA. Management of Perianal Crohn's Disease. Am. J. Gastroenterol. 2023;Publish Ahead of Print.
Alsoud D, Verstockt B, Fiocchi C, Vermeire S. Breaking the therapeutic ceiling in drug development in ulcerative colitis. Lancet Gastroenterol Hepatol. 2021;6:589–595.
pubmed: 34019798
doi: 10.1016/S2468-1253(21)00065-0
Plevris N, Lees CW. Disease Monitoring in Inflammatory Bowel Disease: Evolving Principles and Possibilities. Gastroenterology. 2022;162:1456–75.e1.
pubmed: 35101422
doi: 10.1053/j.gastro.2022.01.024
Shah SC, Colombel JF, Sands BE, Narula N. Systematic review with meta-analysis: mucosal healing is associated with improved long-term outcomes in Crohn’s disease. Aliment Pharmacol Ther. 2016;43:317–333.
pubmed: 26607562
doi: 10.1111/apt.13475
Limketkai BN, Singh S, Jairath V, Sandborn WJ, Dulai PS. US Practice Patterns and Impact of Monitoring for Mucosal Inflammation After Biologic Initiation in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2019;25:1828–1837.
pubmed: 31039246
pmcid: 6799945
doi: 10.1093/ibd/izz081
Wagatsuma K, Yokoyama Y, Nakase H. Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease. Life (Basel). 2021;11:1375.
pubmed: 34947906
pmcid: 8707558
Ghosh S, Sensky T, Casellas F et al. A Global, Prospective, Observational Study Measuring Disease Burden and Suffering in Patients with Ulcerative Colitis Using the Pictorial Representation of Illness and Self-Measure Tool. J Crohns Colitis. 2020;15:228–237.
pubmed: 32722760
pmcid: 7904086
doi: 10.1093/ecco-jcc/jjaa159
Karimi N, Kanazaki R, Lukin A et al. Clinical communication in inflammatory bowel disease: a systematic review of the study of clinician-patient dialogue to inform research and practice. BMJ open. 2021;11:e051053-e.
doi: 10.1136/bmjopen-2021-051053
Rubin DT, Dubinsky MC, Martino S, Hewett KA, Panés J. Communication Between Physicians and Patients with Ulcerative Colitis: Reflections and Insights from a Qualitative Study of In-Office Patient-Physician Visits. Inflamm. Bowel Dis. 2017;23:494–501.
pubmed: 28296817
doi: 10.1097/MIB.0000000000001048
Bennebroek Evertsz F, Hoeks CC, Nieuwkerk PT et al. Development of the patient Harvey Bradshaw index and a comparison with a clinician-based Harvey Bradshaw index assessment of Crohn’s disease activity. J Clin Gastroenterol. 2013;47:850–856.
pubmed: 23632348
doi: 10.1097/MCG.0b013e31828b2196